Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19600462 | 0.86 | ALDH1A1 (0.53) | ALDH1A1CYP3A4MAPTKMT2AMEN1 | |
| SCHEMBL26553682 | 0.84 | ALDH1A1 (0.55) | ALDH1A1CYP3A4MAPTKMT2AMEN1 | |
| SCHEMBL12173945 | 0.84 | MAPT (0.43) | ALDH1A1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL18874604 | 0.84 | ADRA2A (0.46) | ALDH1A1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL19154800 | 0.83 | ROCK2 (0.41) | ALDH1A1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL22388985 | 0.83 | L3MBTL1 (0.45) | ALDH1A1MAPTKMT2AMEN1L3MBTL1 | |
| SCHEMBL132773 | 0.82 | ALDH1A1 (0.78) | ALDH1A1CYP3A4MAPTKMT2AMEN1 | |
| SCHEMBL12285735 | 0.81 | ALDH1A1 (0.60) | ALDH1A1CYP3A4MAPTKMT2AMEN1 | |
| SCHEMBL21120303 | 0.81 | KMT2A (0.43) | ALDH1A1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL22788429 | 0.81 | CA1 (0.44) | ALDH1A1MAPTKMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024036329-A2 | CYTOTOXIC COMPOUNDS AND CONJUGATES THEREOF | SEAGEN INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2023178289-A2 | CAMPTOTHECIN CONJUGATES | SEAGEN INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023061405-A1 | HIGHLY-STABLE TARGETED LINKER-DRUG CONJUGATE | 成都科岭源医药技术有限公司 | 2023-04-20 | — | — | WO | disclosed |
| US-11559558-B2 | Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates | SEAGEN INC. (US) | 2023-01-24 | — | — | US | disclosed |
| WO-2022262789-A1 | ANTITUMOR COMPOUND AND USE THEREOF | 明慧医药（杭州）有限公司 | 2022-12-22 | — | — | WO | disclosed |
| EP-3500574-B1 | SECO-CYCLOPROPAPYRROLOINDOLE COMPOUNDS, ANTIBODY-DRUG CONJUGATES THEREOF, AND METHODS OF MAKING AND USE | BRISTOL MYERS SQUIBB CO (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2018075842-A1 | CONDENSED BENZODIAZEPINE DERIVATIVES AND CONJUGATES MADE THEREFROM | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-26 | — | — | WO | disclosed |
| WO-2018035391-A1 | SECO-CYCLOPROPAPYRROLOINDOLE COMPOUNDS, ANTIBODY-DRUG CONJUGATES THEREOF, AND METHODS OF MAKING AND USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-22 | — | — | WO | disclosed |
| US-20170252458-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MORPHOTEK, INC. | 2017-09-07 | — | — | US | disclosed |
| US-20170218085-A1 | SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY | NOVARTIS AG (CH) | 2017-08-03 | — | — | US | disclosed |
| US-20150104468-A1 | SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY | IRM LLC (BM) | 2015-04-16 | — | — | US | disclosed |
| US-20140065171-A1 | Site-Specific Labeling Methods and Molecules Produced Thereby | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150104468-A1 | SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY | PTMS, DNPEP, PSAT1 | ALDH1A1 2810/4885CYP3A4 2125/4885MAPT 2727/4885 |
| US-11559558-B2 | Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates | CD44, PABPC1, CD47 | ALDH1A1 639/4885CYP3A4 2150/4885MAPT 1886/4885 |
| US-20170252458-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | FOLR1, FOLR2, TUBB1 | ALDH1A1 2699/4885CYP3A4 3838/4885MAPT 305/4885 |
| US-20140065171-A1 | Site-Specific Labeling Methods and Molecules Produced Thereby | PTMS, DNPEP, PSAT1 | ALDH1A1 2362/4885CYP3A4 1469/4885MAPT 2702/4885 |
| US-20170218085-A1 | SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY | PTMS, DNPEP, PSAT1 | ALDH1A1 2362/4885CYP3A4 1469/4885MAPT 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.